Skip Nav Destination
A modified CALGB 10403 in adolescents and young adults with acute lymphoblastic leukemia in Central America
Phase 2 study of PD-1 blockade following autologous transplantation for patients with AML ineligible for allogeneic transplant
Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials
Vemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E–positive LCH
Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up
Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study
Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis
Early cessation of calcineurin inhibitors is feasible post–haploidentical blood stem cell transplant: the ANZHIT 1 study
Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma
A comprehensive analysis of adverse events in the first 30 days of phase 1 pediatric CAR T-cell trials
EASIX-1year and late mortality after allogeneic stem cell transplantation
Human herpesvirus 6–specific T-cell immunity in allogeneic hematopoietic stem cell transplant recipients
Prospective PTCTC trial of myeloablative haplo-BMT with posttransplant cyclophosphamide for pediatric acute leukemias
Hematopoietic stem cell mobilization for allogeneic stem cell transplantation by motixafortide, a novel CXCR4 inhibitor
Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA/DRST study
Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R
FLT3-ITD does not predict inferior prognosis in acute myeloid leukemia patients aged ≥60 years
An international real-world analysis of relapsed/refractory lymphoma occurring during pregnancy
Issue Archive
September 26 2023
In this Issue
Table of Contents
INSIDE BLOOD ADVANCES
REVIEW ARTICLES
SYSTEMATIC REVIEW
Attenuated immunogenicity of SARS-CoV-2 vaccines and risk factors in stem cell transplant recipients: a meta-analysis
Tanaporn Meejun,Karan Srisurapanont,Kasama Manothummetha,Achitpol Thongkam,Nuthchaya Mejun,Nipat Chuleerarux,Anawin Sanguankeo,Kasidis Phongkhun,Surachai Leksuwankun,Jaedvara Thanakitcharu,Bhoowit Lerttiendamrong,Nattapong Langsiri,Pattama Torvorapanit,Navaporn Worasilchai,Rongpong Plongla,Nattiya Hirankarn,Saman Nematollahi,Nitipong Permpalung,Chatphatai Moonla,Olivia S. Kates
CLINICAL TRIALS AND OBSERVATIONS
A modified CALGB 10403 in adolescents and young adults with acute lymphoblastic leukemia in Central America
Clinical Trials & Observations
Juan Rangel-Patiño,Yu Ling Lee-Tsai,Victor Itaí Urbalejo-Ceniceros,Maria Elena Monserrat Luna-Perez,Karla Adriana Espinosa-Bautista,Lauro Fabian Amador,Álvaro Cabrera-García,Carolina Balderas-Delgado,Sergio I Inclan-Alarcon,Yvette Neme-Yunes,Jose Manuel Sanchez-Albarrán,Elia Ixel Apodaca,Luis Meillon-García,Wendy Stock,Roberta Demichelis-Gómez
Phase 2 study of PD-1 blockade following autologous transplantation for patients with AML ineligible for allogeneic transplant
Clinical Trials & Observations
Scott R. Solomon,Melhem Solh,Lawrence E. Morris, Jr.,H. Kent Holland,Lizamarie Bachier-Rodriguez,Xu Zhang,Caitlin Guzowski,Katelin C Jackson,Stacey Brown,Asad Bashey
Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials
Clinical Trials & Observations
Shai Shimony,Yael Flamand,Yannis K. Valtis,Andrew E. Place,Lewis B. Silverman,Lynda M. Vrooman,Andrew M. Brunner,Stephen E. Sallan,Richard M. Stone,Martha Wadleigh,Donna S. Neuberg,Daniel J. DeAngelo,Marlise R. Luskin
Vemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E–positive LCH
Clinical Trials & Observations
Dmitry Evseev,Daria Osipova,Irina Kalinina,Elena Raykina,Anna Ignatova,Evelina Lyudovskikh,Dina Baidildina,Alexander Popov,Vladimir Zhogov,Alexandra Semchenkova,Eugeny Litvin,Natalia Kotskaya,Ekaterina Cherniak,Kirill Voronin,Eugeny Burtsev,Gleb Bronin,Irina Vlasova,Bazarma Purbueva,Olesya Fink,Ekaterina Pristanskova,Irina Dzhukaeva,Elena Erega,Galina Novichkova,Alexey Maschan,Michael Maschan
Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up
Clinical Trials & Observations
Pier Luigi Zinzani,Armando Santoro,Giuseppe Gritti,Pauline Brice,Paul M. Barr,John Kuruvilla,David Cunningham,Justin Kline,Nathalie A. Johnson,Neha Mehta-Shah,Julie Lisano,Rachael Wen,Alev Akyol,Alison J. Moskowitz
Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study
Clinical Trials & Observations
Carol Moreno,Isabelle G. Solman,Constantine S. Tam,Andrew Grigg,Lydia Scarfò,Thomas J. Kipps,Srimathi Srinivasan,Raghuveer Singh Mali,Cathy Zhou,James P. Dean,Edith Szafer-Glusman,Michael Choi
Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis
Clinical Trials & Observations
Vikas Gupta,John Mascarenhas,Marina Kremyanskaya,Raajit K. Rampal,Moshe Talpaz,Jean-Jacques Kiladjian,Alessandro M. Vannucchi,Srdan Verstovsek,Gozde Colak,Debarshi Dey,Claire Harrison
Early cessation of calcineurin inhibitors is feasible post–haploidentical blood stem cell transplant: the ANZHIT 1 study
Clinical Trials & Observations
John Moore,Nada Hamad,David Gottlieb,Ashish Bajel,David Ritchie,David Yeung,Matthew Greenwood,Duncan Purtill,Steven Tran,Annie Solterbeck,Donna Aarons,John Kwan
Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma
Clinical Trials & Observations
Michael Scordo,Jessica R. Flynn,Mithat Gonen,Sean M. Devlin,Allison Parascondola,Ana Alarcon Tomas,Roni Shouval,Jamie Brower,David L. Porter,Stephen J. Schuster,Veronika Bachanova,Joseph Maakaron,Richard T. Maziarz,Andy I. Chen,Loretta J. Nastoupil,Joseph P. McGuirk,Olalekan O. Oluwole,Andrew Ip,Lori A. Leslie,Michael R. Bishop,Peter A. Riedell,Miguel-Angel Perales
HEMATOPOIESIS AND STEM CELLS
Association between busulfan exposure and survival in patients undergoing a CD34+ selected stem cell transplantation
Roni Tamari,Michael Scordo,Binni M. Kunvarjee,Anthony Proli,Andrew Lin,Jessica Flynn,Christina Cho,Sean Devlin,Elizabeth Klein,Farid Boulad,Maria I. Cancio,Kevin J. Curran,Ann A. Jakubowski,Nancy A. Kernan,Andrew L. Kung,Richard J. O’Reilly,Esperanza B. Papadopoulos,Susan Prockop,Andromachi Scaradavou,Brian C. Shaffer,Gunjan Shah,Barbara Spitzer,Boglarka Gyurkocza,Sergio A. Giralt,Miguel-Angel Perales,Jaap Jan Boelens
ETV6 represses inflammatory response genes and regulates HSPC function during stress hematopoiesis in mice
Mackenzie Bloom,Ninad Oak,Rebekah Baskin-Doerfler,Ruopeng Feng,Ilaria Iacobucci,Pradyumna Baviskar,Xujie Zhao,Alexa N. Stroh,Chunliang Li,Patrick Ozark,Heather S. Tillman,Yichao Li,Katherine C. Verbist,Sabrin Albeituni,Danny C. Scott,Moeko T. King,Shannon L. McKinney-Freeman,Mitchell J. Weiss,Jun J. Yang,Kim E. Nichols
IMMUNOBIOLOGY AND IMMUNOTHERAPY

Low leukemia DR score predicts poor response to CAR T-cells but can be raised by neoadjuvant low-dose total tumor irradiation, which improves CAR T-cell response in mice.
A comprehensive analysis of adverse events in the first 30 days of phase 1 pediatric CAR T-cell trials
Clinical Trials & Observations
Sara K. Silbert,Sanna Madan,Elizabeth M. Holland,Seth M. Steinberg,Lauren Little,Toni Foley,Monica Epstein,Angela Sarkisian,Daniel W. Lee,Ekaterina Nikitina,Showri Kakumanu,Eytan Ruppin,Haneen Shalabi,Bonnie Yates,Nirali N. Shah
LYMPHOID NEOPLASIA
Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy–treated mantle cell lymphoma
Anna Nikkarinen,Lavanya Lokhande,Rose-Marie Amini,Mats Jerkeman,Anna Porwit,Daniel Molin,Gunilla Enblad,Arne Kolstad,Riikka Räty,Martin Hutchings,Caroline E. Weibull,Peter Hollander,Sara Ek,Ingrid Glimelius
Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303
David A. Russler-Germain,Kilannin Krysiak,Cody Ramirez,Matthew Mosior,Marcus P. Watkins,Felicia Gomez,Zachary L. Skidmore,Lee Trani,Feng Gao,Susan Geyer,Amanda F. Cashen,Neha Mehta-Shah,Brad S. Kahl,Nancy L. Bartlett,Juan P. Alderuccio,Izidore S. Lossos,Sarah L. Ondrejka,Eric D. Hsi,Peter Martin,John P. Leonard,Malachi Griffith,Obi L. Griffith,Todd A. Fehniger
Sézary syndrome originates from heavily mutated hematopoietic progenitors
Carly M. Harro,Kimberly B. Sprenger,Ricardo A. Chaurio,John J. Powers,Patrick Innamarato,Carmen M. Anadon,Yumeng Zhang,Subir Biswas,Gunjan Mandal,Jessica A. Mine,Carla Cortina,Mate Z. Nagy,Alexandra L. Martin,Katelyn F. Handley,Gustavo J. Borjas,Pei-Ling Chen,Javier Pinilla-Ibarz,Lubomir Sokol,Xiaoqing Yu,Jose R. Conejo-Garcia
MYELOID NEOPLASIA
Combined GLUT1 and OXPHOS inhibition eliminates acute myeloid leukemia cells by restraining their metabolic plasticity
Maria Rodriguez-Zabala,Ramprasad Ramakrishnan,Katrin Reinbach,Somadri Ghosh,Leal Oburoglu,Antoni Falqués-Costa,Kishan Bellamkonda,Mats Ehinger,Pablo Peña-Martínez,Noelia Puente-Moncada,Henrik Lilljebjörn,Jörg Cammenga,Cornelis Jan Pronk,Vladimir Lazarevic,Thoas Fioretos,Anna K. Hagström-Andersson,Niels-Bjarne Woods,Marcus Järås
RED CELLS, IRON, AND ERYTHROPOIESIS
THROMBOSIS AND HEMOSTASIS
Polygenic risk of major depressive disorder as a risk factor for venous thromboembolism
Joey Ward,Ngoc-Quynh Le,Suryakant Suryakant,Jennifer A. Brody,Philippe Amouyel,Anne Boland,Rosemary Bown,Breda Cullen,Stéphanie Debette,Jean-François Deleuze,Joseph Emmerich,Nicholas Graham,Marine Germain,Jana J. Anderson,Jill P. Pell,Donald M. Lyall,Laura M. Lyall,Daniel J. Smith,Kerri L. Wiggins,José Manuel Soria,Juan Carlos Souto,Pierre-Emmanuel Morange,Nicholas L. Smith,David-Alexandre Trégouët,Maria Sabater-Lleal,Rona J. Strawbridge
TRANSPLANTATION
EASIX-1year and late mortality after allogeneic stem cell transplantation
Clinical Trials & Observations
Lambros Kordelas,Tobias Terzer,Ted Gooley,Chris Davis,Brenda M. Sandmaier,Mohamed Sorror,Olaf Penack,Nigel D. E. Schaeper,Igor W. Blau,Dietrich Beelen,Aleksandar Radujkovic,Peter Dreger,Thomas Luft
Human herpesvirus 6–specific T-cell immunity in allogeneic hematopoietic stem cell transplant recipients
Clinical Trials & Observations
Maddalena Noviello,Francesca Lorentino,Elisabetta Xue,Sara Racca,Giulia Furnari,Veronica Valtolina,Edoardo Campodonico,Roee Dvir,Maria Teresa Lupo-Stanghellini,Fabio Giglio,Simona Piemontese,Daniela Clerici,Chiara Oltolini,Elena Tassi,Valeria Beretta,Francesca Farina,Daniele Mannina,Anna Ardemagni,Luca Vago,Massimo Bernardi,Consuelo Corti,Jacopo Peccatori,Massimo Clementi,Fabio Ciceri,Chiara Bonini,Raffaella Greco
Prospective PTCTC trial of myeloablative haplo-BMT with posttransplant cyclophosphamide for pediatric acute leukemias
Clinical Trials & Observations
Juan C. Fierro-Pineda,Hua-Ling Tsai,Amanda Blackford,Andrew Cluster,Emi Caywood,Jignesh Dalal,Jeffrey Davis,Maarten Egeler,Jeffrey Huo,Michelle Hudspeth,Amy Keating,Susan S. Kelly,Joerg Krueger,Dean Lee,Leslie Lehmann,Lisa Madden,Benjamin Oshrine,Michael A. Pulsipher,Terry Fry,Heather J. Symons
RESEARCH LETTERS
Hematopoietic stem cell mobilization for allogeneic stem cell transplantation by motixafortide, a novel CXCR4 inhibitor
Clinical Trials & Observations
Zachary D. Crees,Michael P. Rettig,Asad Bashey,Steven M. Devine,Samantha Jaglowski,Fei Wan,Amy Zhou,Melinda Harding,Abi Vainstein-Haras,Ella Sorani,Irit Gliko-Kabir,Brenda J. Grossman,Peter Westervelt,John F. DiPersio,Geoffrey L. Uy
Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA/DRST study
Clinical Trials & Observations
Francis Ayuk,Nico Gagelmann,Bastian von Tresckow,Gerald Wulf,Kai Rejeski,Matthias Stelljes,Olaf Penack,Claudia D. Baldus,Nicolaus Kröger,Wolfgang Bethge,Peter Dreger
Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R
Clinical Trials & Observations
Rahul Lakhotia,Kieron Dunleavy,Jeremy S. Abramson,Brian K. Link,Bayard L. Powell,Christopher Melani,Andrea N. Lucas,Seth M. Steinberg,Jonathan W. Friedberg,Brad S. Kahl,Richard F. Little,Nancy L. Bartlett,Ariela Noy,Wyndham H. Wilson,Mark Roschewski
FLT3-ITD does not predict inferior prognosis in acute myeloid leukemia patients aged ≥60 years
Clinical Trials & Observations
Shai Shimony,Geoffrey Fell,Evan C. Chen,Harrison K. Tsai,Martha Wadleigh,Eric S. Winer,Jacqueline S. Garcia,Marlise R. Luskin,Maximilian Stahl,Donna S. Neuberg,Daniel J. DeAngelo,R. Coleman Lindsley,Richard M. Stone
An international real-world analysis of relapsed/refractory lymphoma occurring during pregnancy
Clinical Trials & Observations
Faheem Farooq,Justin S. Brandt,Elyce Cardonick,Evgeniya Polushkina,Julie Vose,Sairah Ahmed,Praveen Ramakrishnan Geethakumari,Adam J. Olszewski,Hesham Yasin,Umar Farooq,Nada Hamad,Yong Lin,Charlotte Maggen,Robert Fruscio,Mina Mhallem Gziri,Karina Dahl Steffensen,Frédéric Amant,Andrew M. Evens
A timeline of genetic variant enrichment: from multiple myeloma diagnosis to myeloma-associated myeloid malignancy
Ariel Kleman,Arun Singavi,Lauren Pommert,Angela J. Mathison,Parameswaran Hari,Binod Dhakal,Meera Mohan,Siegfried Janz,Jennifer M. Knight,Mithun V. Shah,Carolina Schinke,Robert Burns,George Francis Steinhardt,Sridhar Rao,Karen Carlson
Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients
Matthew R. Schuelke,Hamid Bassiri,Edward M. Behrens,Scott Canna,Colleen Croy,Amanda DiNofia,Kandace Gollomp,Stephan Grupp,Michele Lambert,Arathi Lambrix,Shannon L. Maude,Regina Myers,Haley Newman,Whitney Petrosa,Alix Seif,Kathleen E. Sullivan,David T. Teachey,Caroline Diorio
COMMENTARIES
ERRATA
-
Cover Image
Cover Image
Schematic overview of B-cell differentiation deregulation by the constitutive activation of IRF4 and/or NF-κB, which induces the oncogenic transcription program in large B-cell lymphoma-IRF4. See the article by Salaverria et al.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Advertisement intended for health care professionals
Remission after rituximab for HHV8+ MCD: what next?
Clinical Trials & Observations